Patients in CBD-only, low-THC, limited-program, and no-program states ( Idaho, Indiana, Iowa, Kansas, North Carolina, South Carolina, Tennessee, Wisconsin, Wyoming, and American Samoa) are at the greatest risk of being left behind. Many residents use cannabis or cannabinoid products therapeutically, but their states may not provide a meaningful way to document medical status, access regulated medical products, or participate in a recognized medical cannabis system.
These states should create or prepare patient documentation pathways, including a medical cannabis registry, provisional documentation process, or other medical-status system. Where limited cannabinoid licenses already exist, states should review those licenses for transition into a medical framework with product safety, patient verification, medical-only records, and state verification for eligible businesses. Federal policy is moving, and states with weak or no medical cannabis programs cannot afford to leave patients with no practical path forward.
Your Governor and State Representatives need to hear from you, TODAY!
Use the sample letter below to tell them about the June 26, 2026, DEA registration deadline and send them a copy of ASA's State Preparedness for Federal Cannabis Regulation & Enforcement: Part 1, State Actions Needed to Preserve & Protect Patient Access.
Share this page
